# Tempo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tempo-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.tempothera.com
- Total disclosed funding: $16M
- Latest round: Series A (Mar 1, 2024)
- Investors on record: 1

## About

Founded in 2014 by Westbrook Weaver (CEO) and Donald Griffin (CSO), and based in California, US, Tempo Therapeutics, Inc. operates as a biotechnology research company that develops and manufactures tissue engineering solutions for regenerative medicine using its Microporous Annealed Particle technology. In March 2024, Tempo Therapeutics, Inc. raised USD 16.33 million in Series A funding co-led by investors Johnson & Johnson Innovation and Galaxy Sirius Partners, with participation from other investors.

The firm pioneers tissue engineering biotechnology using its proprietary MAP (Microporous Annealed Particle) material science technology. MAP enables the creation of injectable porous scaffolds for regenerative medicine, modulating patients' immune cells for regenerative responses. Their biosurgery products address soft tissue reconstructions, improving outcomes by promoting tissue strength and function. Additionally, Tempo develops novel therapies in various therapeutic areas using MAP technology. 

The company intends to use the March 2024 funding to take its synthetic tissue scaffold candidates into clinical trials and advance its Microporous-Annealed-Particle (MAP) technology platform.

## Funding rounds

- Series A, Mar 1, 2024, $16M — Johnson & Johnson Innovation

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A